Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Feb;30(2):103-109.
doi: 10.1093/ajh/hpw105. Epub 2016 Sep 8.

Use of Aldosterone Antagonists for Treatment of Uncontrolled Resistant Hypertension

Tanja Dudenbostel  1 , David A Calhoun  2
Affiliations
Review

Use of Aldosterone Antagonists for Treatment of Uncontrolled Resistant Hypertension

Tanja Dudenbostel et al. Am J Hypertens. 2017 Feb.

Abstract

Background: Multiple studies indicate that primary aldosteronism (PA) is common in patients with resistant hypertension, with an estimated prevalence of approximately 20%. Additional studies suggest that beyond this 20% of patients with classical PA, there is a larger proportion of patients with lesser degrees of hyperaldosteronism which contributes even more broadly to antihypertensive treatment resistance. Given these observations, it is intuitive that use of aldosterone antagonists will provide antihypertensive benefit in patients with resistant hypertension and evidence of aldosterone excess. Intriguingly, however, are clinical findings demonstrating substantive benefit of aldosterone antagonists in patients with resistant hypertension, but without demonstrative evidence of hyperaldosteronism, that is, with seemingly normal or even low aldosterone levels.

Conclusion: Spironolactone is clearly established as the most effective fourth agent for treatment of uncontrolled resistant hypertension. Emerging observations suggest a further role of spironolactone for counteracting the effects of diet high in sodium, particularly in obese, hypertensive patients.

Keywords: aldosterone; aldosterone antagonists; blood pressure; hypertension; obesity; resistant hypertension; spironolactone..

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Spironolactone-induced reduction in SBP (filled bars) and DBP (open bars) at 6-week, 3-month, and 6-month follow-up in subjects with resistant hypertension (upper panel). Spironolactone-induced reduction in SBP and DBP at 6-week, 3-month, and 6-month follow-up in subjects with PA (filled bars) and without PA (non-PA: open bars)(lower panel). Abbreviations: DBP, diastolic blood pressure; PA, primary aldosteronism; SBP, systolic blood pressure.
Figure 2.
Figure 2.
Mean 24-hour UAldo levels to quartiles of BMI in men vs. women. White columns represent women and black columns represent men. Abbreviations: BMI, body mass index; Ualdo, urinary aldosterone
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

  • The endothelial mineralocorticoid receptor: Contributions to sex differences in cardiovascular disease.
    Moss ME, Carvajal B, Jaffe IZ. Moss ME, et al. Pharmacol Ther. 2019 Nov;203:107387. doi: 10.1016/j.pharmthera.2019.06.009. Epub 2019 Jul 2. Pharmacol Ther. 2019. PMID: 31271793 Free PMC article. Review.
  • The renin-angiotensin system in cardiovascular autonomic control: recent developments and clinical implications.
    Miller AJ, Arnold AC. Miller AJ, et al. Clin Auton Res. 2019 Apr;29(2):231-243. doi: 10.1007/s10286-018-0572-5. Epub 2018 Nov 9. Clin Auton Res. 2019. PMID: 30413906 Free PMC article. Review.
  • The Effect of Aldosterone on Cardiorenal and Metabolic Systems.
    Otsuka H, Abe M, Kobayashi H. Otsuka H, et al. Int J Mol Sci. 2023 Mar 11;24(6):5370. doi: 10.3390/ijms24065370. Int J Mol Sci. 2023. PMID: 36982445 Free PMC article. Review.
  • [Austrian Consensus on High Blood Pressure 2019].
    Weber T, Arbeiter K, Ardelt F, Auer J, Aufricht C, Brandt MC, Dichtl W, Ferrari J, Föger B, Henkel M, Hohenstein-Scheibenecker K, Horn S, Kautzky-Willer A, Kepplinger E, Knoflach M, Koppelstätter C, Mache C, Marschang P, Mayer G, Metzler B, Oberbauer R, Obermair F, Obermayer-Pietsch B, Perl S, Pilz S, Prischl FC, Podczeck-Schweighofer A, Rebhandl E, Rohla M, Roller-Wirnsberger R, Saely CH, Siostrzonek P, Slany J, Stoschitzky K, Waldegger S, Wenzel RR, Weiss T, Wirnsberger G, Winhofer-Stöckl Y, Zweiker D, Zweiker R, Watschinger B; Österreichische Gesellschaft für Hypertensiologie; Österreichische Atherosklerosegesellschaft; Österreichische Diabetes Gesellschaft; Österreichische Gesellschaft für Internistische Angiologie; Österreichische Gesellschaft für Nephrologie; Österreichische Kardiologische Gesellschaft; Österreichische Gesellschaft für Neurologie; Österreichische Schlaganfall-Gesellschaft; Österr. Gesellschaft für Allgemeinmedizin; Österr. Gesellschaft für Geriatrie; Österreichische Gesellschaft für Endokrinologie und Stoffwechsel; Österreichische Gesellschaft für Innere Medizin; Österreichische Gesellschaft für Kinder- und Jugendheilkunde. Weber T, et al. Wien Klin Wochenschr. 2019 Nov;131(Suppl 6):489-590. doi: 10.1007/s00508-019-01565-0. Wien Klin Wochenschr. 2019. PMID: 31792659 German.
  • Resistant and refractory hypertension: two sides of the same disease?
    Muxfeldt ES, Chedier B, Rodrigues CIS. Muxfeldt ES, et al. J Bras Nefrol. 2019 Apr-Jun;41(2):266-274. doi: 10.1590/2175-8239-jbn-2018-0108. Epub 2018 Dec 6. J Bras Nefrol. 2019. PMID: 30525180 Free PMC article.
See all "Cited by" articles

References

    1. Calhoun DA, Nishizaka MK, Zaman MA, Thakkar RB, Weissmann P. Hyperaldosteronism among Black and White subjects with resistant hypertension. Hypertension 2002; 40:892–896. - PubMed
    1. Eide IK, Torjesen PA, Drolsum A, Babovic A, Lilledahl NP. Low-renin status in therapy-resistant hypertension: a clue to efficient treatment. J Hypertens 2004; 22:2217–2226. - PubMed
    1. Gallay BJ, Ahmad S, Xu L, Toivola B, Davidson RC. Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio. Am J Kidney Dis 2001; 37:699–705. - PubMed
    1. Strauch B, Zelinka T, Hampf M, Bernhardt R, Widimsky J., Jr Prevalence of primary hyperaldosteronism in moderate to severe hypertension in the Central Europe region. J Hum Hypertens 2003; 17:349–352. - PubMed
    1. Gaddam KK, Nishizaka MK, Pratt-Ubunama MN, Pimenta E, Aban I, Oparil S, Calhoun DA. Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. Arch Intern Med 2008; 168:1159–1164. - PMC - PubMed

MeSH terms

Substances